Literature DB >> 15864276

ERBB receptors and cancer: the complexity of targeted inhibitors.

Nancy E Hynes1, Heidi A Lane.   

Abstract

ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumours, and clinical studies indicate that they have important roles in tumour aetiology and progression. Accordingly, these receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ERBB inhibitors are now used in the clinic. We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864276     DOI: 10.1038/nrc1609

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  1181 in total

Review 1.  Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab.

Authors:  Bing-Bing Yang; Peggy Lum; Alin Chen; Rosalin Arends; Lorin Roskos; Brian Smith; Juan José Pérez Ruixo
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

Review 3.  Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?

Authors:  M Ponz-Sarvisé; J Rodríguez; A Viudez; A Chopitea; A Calvo; J García-Foncillas; I Gil-Bazo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 4.  New approaches in angiogenic targeting for colorectal cancer.

Authors:  Aleix Prat; Esther Casado; Javier Cortés
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

5.  Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.

Authors:  Larissa Sweeny; Andrew Prince; Neel Patel; Lindsay S Moore; Eben L Rosenthal; Brian B Hughley; Jason M Warram
Journal:  Laryngoscope       Date:  2016-08-31       Impact factor: 3.325

Review 6.  [Molecular pathology of the lungs. New perspectives by next generation sequencing].

Authors:  C Vollbrecht; K König; L Heukamp; R Büttner; M Odenthal
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

7.  Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.

Authors:  Odelia Cooper; Adam Mamelak; Serguei Bannykh; John Carmichael; Vivien Bonert; Stephen Lim; Galen Cook-Wiens; Anat Ben-Shlomo
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 8.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

9.  EGFR expression in circulating tumor cells from high-grade metastatic soft tissue sarcomas.

Authors:  Alexcia Camila Braun; Celso Abdon Lopes de Mello; Marcelo Corassa; Emne Ali Abdallah; Ana Cláudia Urvanegia; Vanessa Silva Alves; Bianca C T C P Flores; Mônica Díaz; Ulisses Ribaldo Nicolau; Virgilio Souza E Silva; Vinicius Calsavara; Patrizia Paterlini-Brechót; Ludmilla Thomé Domingos Chinen
Journal:  Cancer Biol Ther       Date:  2018-03-21       Impact factor: 4.742

10.  Optimal Objective-Based Experimental Design for Uncertain Dynamical Gene Networks with Experimental Error.

Authors:  Daniel N Mohsenizadeh; Roozbeh Dehghannasiri; Edward R Dougherty
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2016-08-25       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.